Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

Roche’s fene­bru­ti­nib pro­gram in mul­ti­ple scle­ro­sis has been put on par­tial clin­i­cal hold over po­ten­tial cas­es of drug-in­duced liv­er in­jury, the com­pa­ny said Thurs­day. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER